Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of adenovirus infection on the long-term cardiovascular and other outcomes following CAR T-cell therapy: A propensity-matched cohort study

Aakriti Adhikari, Abat Khan, Abdul Wali Khan, Carlos H Silva Rondon, Fernando Vargas Madueno, Jose D. Sandoval-Sus, Furha Cossor

Blood (2025) 146 (Supplement 1): 7683.

https://doi.org/10.1182/blood-2025-7683

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Blood (2025) 146 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2025-1959

Published: 2025

Journal Articles

Rituximab plus lenalidomide (R²) versus standard therapies in follicular lymphoma: A systematic review and meta-analysis of randomized controlled trials

Blood (2025) 146 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2025-1828

Published: 2025

Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown

Blood (2024) 144 (Supplement 1): 987.

https://doi.org/10.1182/blood-2024-198452

Published: 2024

Journal Articles

Incidence of Secondary Malignancy after Treatment with Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cell Therapies

Can Jones, Amneh A Fares, Diana Martinez, Jennifer M Logue, Carlos Silva Rondon, Fernando Vargas Madueno, Nina Nguyen, Hugo Francisco Fernandez, Julio C. Chavez, Jose Sandoval-Sus

Blood (2024) 144 (Supplement 1): 7241.

https://doi.org/10.1182/blood-2024-206293

Published: 2024

Journal Articles

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

Stephanie Boisclair, MD, Richie Uba, PharmD, Amanda Brahim, PharmD, Fernando Vargas Madueno, MD, Julio C. Chavez, MD, Jose Sandoval-Sus, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-143226

Published: 2020

Journal Articles

The Novel Translocation t(4;15)(q31;q22) in AML Is Associated with a Proliferative Phenotype in the Presence of All-Trans Retinoic Acid (ATRA)

Justin M Watts, MD, Aymee Perez, PhD, Fernando Vargas, MD, Yao-Shan Fan, MD PhD, Alejandra Weisman, Ana Rodriguez, Omar Lopez, Francisco Vega, MD PhD, Ronan T Swords, MD PhD FRCPI, FRCPath, Arthur Zelent, PhD

Blood (2016) 128 (22): 1526.

https://doi.org/10.1182/blood.V128.22.1526.1526

Published: 2016

Journal Articles

Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology

Yamina Lilliana Carattini, MCLS, Terrence Bradley, MD, Fernando Vargas, MD, Justin M Watts, MD, Jennifer R Chapman, MD, German Campuzano-Zuluaga, MD, Francisco Vega, MD PhD, Deukwoo Kwon, PhD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2016) 128 (22): 5527.

https://doi.org/10.1182/blood.V128.22.5527.5527

Published: 2016

Journal Articles

Mutational Frequency in Hispanic Vs. Non-Hispanic Patients with Acute Myeloid Leukemia (AML)

Jorge Monge, MD, Christine Vaupel, PhD, Ronan T Swords, MD PhD FRCPI, FRCPath, Terrence Bradley, MD, Ryan Chapman, DO, Naiomi Gunaratne, Jennifer R Chapman, MD, Francisco Vega, MD PhD, Eric Padron, MD, Fernando Vargas, MD, Jeff Hall, PhD, Justin M Watts, MD

Blood (2016) 128 (22): 2796.

https://doi.org/10.1182/blood.V128.22.2796.2796

Published: 2016

Journal Articles

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

Diana M Byrnes, MD MPH, Christopher R Dermarkarian, BS, Ryan Kahn, BA, MHS, Deukwoo Kwon, PhD, Fernando Vargas, MD, Judith Hurley, MD, Justin M. Watts, MD, Jonathan H. Schatz, MD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2016) 128 (22): 5973.

https://doi.org/10.1182/blood.V128.22.5973.5973

Published: 2016

Journal Articles

In Acute Myeloid Leukemia (AML), Targeting the Histone Methyltransferase EZH2 Promotes Differentiation, Impairs Clonogenic Survival and Augments the Anti-Leukemic Effects of the Retinoid, All-Trans-Retinoic Acid (ATRA)

Ronan T. Swords, MDPhDFRCPI FRCPath, Aymee Perez, PhD, Ana Rodriguez, Justin M. Watts, MD, Tino Schenk, PhD, Fernando Vargas, MD, Roy Elias, Arthur Zelent, PhD

Blood (2015) 126 (23): 3786.

https://doi.org/10.1182/blood.V126.23.3786.3786

Published: 2015

Journal Articles

The Small Molecule Img-98, a Potent and Selective Inhibitor of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation Effects of ATRA in a Pre-Clinical Model of AML

Ronan T. Swords, MDPhDFRCPI FRCPath, Aymee Perez, PhD, Ana Rodriguez, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Hugh Y. Rienhoff, Jr., MD, Arthur Zelent, PhD

Blood (2015) 126 (23): 460.

https://doi.org/10.1182/blood.V126.23.460.460

Published: 2015

Journal Articles

A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy

Diana Azzam, PhD, Claude-Henry Volmar, PhD, Al-Ali Hassan, PhD, Aymee Perez, PhD, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Francisco Vega, MD PhD, Arthur Zelent, PhD, Christopher R. Cogle, MD, Claes Wahlestedt, PhD, Ronan T. Swords, MDPhDFRCPI FRCPath

Blood (2015) 126 (23): 1352.

https://doi.org/10.1182/blood.V126.23.1352.1352

Published: 2015

Journal Articles

Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia

Ronan T. Swords, MDPhDFRCPI FRCPath, Tino Schenk, PhD, Sven Stengel, PhD, Veronica Sylvina Gil, PhD, Kevin R. Petrie, PhD, Aymee Perez, PhD, Rodriguez Ana, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Arthur Zelent, PhD

Blood (2015) 126 (23): 1363.

https://doi.org/10.1182/blood.V126.23.1363.1363

Published: 2015

Journal Articles

The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro

Ronan T. Swords, MDPhDFRCPI FRCPath, Shaun Brothers, PhD, Nagi Ayad, PhD, Aymee Perez, PhD, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Ana Rodriguez, Shawn Johnstone, PhD, Jeffrey Albert, Joseph Collard, Arthur Zelent, PhD, Claes Wahlestedt, PhD

Blood (2015) 126 (23): 2552.

https://doi.org/10.1182/blood.V126.23.2552.2552

Published: 2015

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Impact of adenovirus infection on the long-term cardiovascular and other outcomes following CAR T-cell therapy: A propensity-matched cohort study

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Rituximab plus lenalidomide (R²) versus standard therapies in follicular lymphoma: A systematic review and meta-analysis of randomized controlled trials

Incidence of Secondary Malignancy after Treatment with Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cell Therapies

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

The Novel Translocation t(4;15)(q31;q22) in AML Is Associated with a Proliferative Phenotype in the Presence of All-Trans Retinoic Acid (ATRA)

Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology

Mutational Frequency in Hispanic Vs. Non-Hispanic Patients with Acute Myeloid Leukemia (AML)

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

In Acute Myeloid Leukemia (AML), Targeting the Histone Methyltransferase EZH2 Promotes Differentiation, Impairs Clonogenic Survival and Augments the Anti-Leukemic Effects of the Retinoid, All-Trans-Retinoic Acid (ATRA)

The Small Molecule Img-98, a Potent and Selective Inhibitor of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation Effects of ATRA in a Pre-Clinical Model of AML

A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy

Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia

The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only